{"id":595358,"date":"2022-04-11T15:06:01","date_gmt":"2022-04-11T15:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=595358"},"modified":"2022-04-11T15:06:01","modified_gmt":"2022-04-11T15:06:01","slug":"congenital-hyperinsulinism-market-to-accelerate-substantially-during-the-forecast-period-delveinsight-key-companies-rezolute-zealand-pharma-xeris-eiger-biopharma-amidebio-and-recordati","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/congenital-hyperinsulinism-market-to-accelerate-substantially-during-the-forecast-period-delveinsight-key-companies-rezolute-zealand-pharma-xeris-eiger-biopharma-amidebio-and-recordati_595358.html","title":{"rendered":"Congenital Hyperinsulinism Market to Accelerate Substantially During the Forecast Period – DelveInsight | Key Companies – Rezolute, Zealand Pharma, Xeris, Eiger BioPharma, AmideBio and Recordati"},"content":{"rendered":"
\n
\"Congenital<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Congenital Hyperinsulinism Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Congenital Hyperinsulinism Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n

The Congenital Hyperinsulinism market report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Congenital<\/p>\n

Congenital Hyperinsulinism: An Overview<\/strong><\/p>\n

Congenital hyperinsulinism (CHI) is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent occurrences of low blood sugar (hypoglycemia). In infants and young children, these occurrences are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.<\/em><\/p>\n

The severity of Congenital Hyperinsulinism varies widely among affected individuals, even among members of the same family. About 60% of infants with this condition experience a hypoglycemic episode within the first month of life. Other affected children develop hypoglycemia by early childhood.<\/em><\/p>\n

Congenital Hyperinsulinism Market Key Facts<\/strong><\/p>\n